The study developed by Li et al. [96] evaluated the effect of oxaliplatin (a new third-generation platinum-based chemotherapy drug); the authors pointed out that oxaliplatin can increase the production of ROS and then can induce the overactivation of PARP1, the depolarization of mitochondria and the nuclear translocation of apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor (MIF), leading to parthanatos in oral cancer. This evidence concerns the gene PARP1 and lip and oral cavity carcinoma.